Cannabidiol and SARS-CoV-2 Infection

Alexandre Vallée*

Department of Epidemiology-Data-Biostatistics, Delegation of Clinical Research and Innovation (DRCI), Foch Hospital, Suresnes, France

Cannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded by SARS-CoV-2 and as an antiviral agent to prevent the viral infection. Furthermore, recent studies have shown the possible action of CBD as an antagonist of cytokine release syndromes. In the SARS-CoV-2 pathophysiology, the angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infection. The WNT/β-catenin pathway and PPARγ interact in an opposite manner in many diseases, including SARS-CoV-2 infection. CBD exerts its activity through the interaction with PPARγ in SARS-CoV-2 infection. Thus, we can hypothesize that CBD may counteract the inflammatory process of SARS-CoV-2 by its interactions with both ACE2 and the interplay between the WNT/β-catenin pathway and PPARγ. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible role of CBD should be investigated by clinical trials to show its effectiveness.

Keywords: COVID-19, Wnt/β-catenin pathway, PPARγ, ACE2, cannabidiol, SARS-CoV-2

INTRODUCTION

Several studies have been investigated to immunize or cure the COVID-19 disease. However, as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) evolved, new mutants can appear to infect and recombine their different hosts (1). While many of applied therapies are promising, they may induce some negative side effects (2, 3). Therefore, it is imperative to investigate new therapeutic strategies with effective treatment showing no or less side effects. In complement to vaccines, the only effective way in the prevention of COVID-19, natural agents may participate in SARS-CoV-2 (4, 5). One possible strategy is the use of cannabidiol (CBD) which exhibits anti-inflammatory and immune-suppressive effects in preclinical models of COVID-19. Nevertheless, very few studies have synthesized the different pathways which could explain the possible effects of CBD in SARS-CoV-2 infection. Thus, this review focuses on the different actions of CBD in SARS-CoV-2 infection and then the possible effects of CBD by interacting with both the WNT/β-catenin pathway and PPARγ expression in this viral disease.

CANNABIDIOL

CBD, a member of the cannabinoid class produced by Cannabis sativa, presents many actions in diseases, as antiviral inflammatory responses (6). However, the biologic actions of CBD remain
unclear (7). Different solutions of CBD have been approved as drug by the FDA in the USA, such as therapy in epilepsy (8). Few reports have shown the interest of CBD in SARS-CoV-2 infection while its beneficial effects have been observed in viral diseases, including hepatitis C (9, 10).

**CBD AND THE PROTEINS ENCODED BY SARS-COV-2**

The SARS-CoV-2 genome, which encodes for several proteins, needs to replicate itself to infect humans (11, 12). These proteins were, for example, SARS-CoV-2Mpro, glycoprotein (S), notorious spike (S) protein (recognizing ACE2 in the first step of infection), chymotrypsin-like main protease, papain-like protease, RNA polymerase (synthesizing viral RNA), and the RNA-cleaving endoribonuclease (responsible for SARS-CoV-2 progression) (12).

A recent study presented an interesting finding in natural products, as cannabidiol (CBD) for the treatment of the COVID-19 disease (13). In their study, they found that CBD and its metabolite 7-OH-CBD can block SARS-CoV-2 replication. CBD acts after viral entry by reversing the transcription of host genes and their expression. CBD can increase the IRE1-alpha RNase endoplasmic reticulum stress response and the interferon pathways (13). The primary target for entry into host cells has been identified to be the multifunctional protein angiotensin-converting enzyme-related carboxypeptidase (ACE2) discovered simultaneously by Donoghue et al. and Tipnis et al. (14, 15). In COVID patients, the ACE2 protein level significantly increases in both alveolar tissue and bronchial epithelium of diabetic patients (16), and this can partly explain the high rate of infectivity of SARS-CoV-2 in some patients, as elderly and infants (17). In the SARS-CoV-2 pathophysiology, angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infecting humans (18). SARS-CoV-2 uses its spike protein S1 to enter cells by interacting with the ACE2 receptor on the cell surface membrane. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a major cell receptor to infect humans (19–22). SARS-CoV-2 infection interacts with ACE2 in lung tissue by binding with the spike (S) viral protein—a 1,273 amino acid-long protein (23). Another study has shown that the intestinal epithelium presents increased levels of ACE2 protein and that the SARS-CoV-2 spike protein may have a major role by stimulating epithelial damages in the intestinal mucosa responsible for inflammation (24).

The link between ACE2 and the S-protein of SARS-CoV-2 results in the release of the RNA of SARS-CoV-2 into the host cell and in the convert of the viral genome RNA into replicase polyproteins 1ab and pp1a. Polyproteins 1ab and pp1a are cleaved into small products by proteinases (25). SARS-CoV-2Mpro plays a major role in the mechanism action of polyproteins (26).

Recently, Raj et al. reported, in their preliminary and in vitro study, that CBD can downregulate SARS-CoV-2 infection into two pathways (27) (Table 1). CBD can bind to SARS-CoV-2Mpro by blocking its transcription, and CBD can interact as an agonist of the CB2 receptor. These two activities can reduce the secretion of pro-inflammatory cytokines in lung cells (27).

Moreover, CBD can activate the CB2 receptor to decrease the inflammatory macrophage release mechanism into the lungs (35) and can reduce the immune pathological mechanisms of viral infection (36). The SARS-CoV-2Mpro downregulation is not associated with side effects in humans and remains at this stage as one the best molecular targets for decreasing the coronavirus replication (37, 38). Thus, CBD, by acting as an agonist of the CB2 receptor, can decrease the activity of SARS-CoV-2Mpro and can downregulate the viral replication due to its binding affinity (27). At this date, SARS-CoV-2Mpro inhibitors are not toxic in humans (26).

**CBD AND THE CYTOKINE STORM IN SARS-COV-2 INFECTION**

The use of CBD can decrease the activity of inflammatory transcription factors, including AP-1, NF-kB, and NFAT pathways. This activity of CBD results in the decrease in the secretion of cytokines such as IL-6 and TNF-α (39). Moreover, the use of CBD in the murine model of asthma was associated with a decrease in different cytokines (40). Among COVID-19 patients, the use of CBD can be beneficial against the cytokine release syndrome but should be proved by clinical trials. CBD has been recently considered as a possible drug in the treatment of SARS-CoV-2 (41–43). This molecule can decrease the release of proinflammatory cytokines responsible for inflammation during SARS-CoV-2 infection (4). CBD can enhance the interferon pathway which leads to the activation of the host immune response to viral pathogens (13). The interferon pathway is a well-known signaling targeted as a possible treatment for COVID-19 (44). Moreover, recent findings highlighted the potential suppressor action of CBD on cytokine production in macrophages (45). Moreover, CBD can downregulate the expression of COX-2, TNF-α, IL-6, CCL2, and other cytokines in a WI-38 lung fibroblast cell line model with SARS-CoV-2 infection (28), as observed in a lung epithelial cell model with the decrease in IL-6 and IL-8 secretion (29) and in intranasal of Poly I:C-induced acute respiratory viral infection of COVID-19 (30) (Table 1).

**CBD AND ANTIVIRAL ACTIONS IN SARS-COV-2 INFECTION**

CBD can decrease the activity of both TMPRSS2 enzymes and ACE2 acting in different viral gateways (i.e., oral, lung, intestinal epithelium) which are major issues for SARS-CoV-2 invasion (31). The possible action of CBD for the treatment of COVID-19 has been observed with the use of polycytidyl acid poly (I: C) (as a synthetic analogue of viral double-stranded RNA), inducing ARDS, in mice (32). Moreover, an in vitro investigation of a mixture of terpene with CBD use in human coronavirus E229i, as the combination of NT-VRL-1 (terpene-based formulation) with CBD, enhanced the antiviral effect (34). Furthermore, it was observed that CBD in combination with 7-OH-CBD can be used to lower SARS-CoV-2 infection occurring in patients (13) (Table 1).
CBD AND PERSPECTIVES IN SARS-COV-2 INFECTION

CBD appears to be a safe molecule for humans, as observed in different conducted trials (46). However, no data are published for the real efficacy and toxicity of CBD in humans for the COVID-19 disease. A lack of data exists to clearly state the use of CBD in SARS-CoV-2 infection as a therapy in addition to other drugs. Future clinical trials should be implemented to test the potential of CBD in COVID-19 patients to target the cytokine storm, the viral infection, and then the prevention of pulmonary fibrosis. In the different known pathological conditions, CBD efficacy depends on the dose and its bioavailability. Thus, different concentrations of CBD should be investigated to understand its possible effects. Moreover, the drug–drug interactions between CBD and other treatments are required to be investigated in COVID-19 patients, and at this stage a lack of studies remains still present. A recent study has shown that CBD could be a stronger antiviral agent than other drugs, such as lopinavir and remdesivir (27). Nevertheless, there are few research articles which highlight the potential action of CBD in COVID-19 infection (27). Nevertheless, there are few research articles which highlight the potential action of CBD in COVID-19 infection (27). Nevertheless, there are few research articles which highlight the potential action of CBD in COVID-19 infection (27). Nevertheless, there are few research articles which highlight the potential action of CBD in COVID-19 infection (27). Nevertheless, there are few research articles which highlight the potential action of CBD in COVID-19 infection (27).

counteract the viral entry and viral replication in SARS-CoV-2 infection (33). CBD exerts its activity through the interaction with PPARγ in COVID-19 infection (4, 33). PPARγ (peroxisome proliferator-activated receptor gamma) is a ligand-activated transcription factor which binds PPREs (PPAR-response elements). PPARγ is implicated in many pathophysiological mechanisms, including cell differentiation, protein metabolism, lipid metabolism, carcinogenesis (49), adipocyte differentiation, insulin sensitivity, and inflammation (50, 51). PPARγ ligands can be synthetic or natural, as CBD (4, 52, 53). PPARγ agonism in resident alveolar macrophages limits pulmonary inflammation and enhances host recovery following respiratory viral infections (54). PPARγ activation is responsible for the control of cytokine oversecretion with consequent amelioration of the tissue damages. COVID-19 survivors can develop postinfectious sequelae with persistently impaired lung function and pulmonary fibrosis (55). PPARγ receptors may be potential therapeutic targets in fibrotic lung diseases, due to their action of controlling fibroblast/myofibroblast activation and collagen secretion in murine models. Indeed, CBD can reduce pulmonary inflammation and fibrosis in animal models of asthma (40). CBD, as a PPARγ receptor agonist, could potentially be a therapeutic strategic way in COVID-19 patients. By a PPARγ-dependent signaling, CBD can prevent the inflammatory response of the SARS-CoV-2 spike protein in Caco-2-cells (33) (Table 1). This action is coupled with the inhibition of IL-1β, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection (33).

HYPOTHESIS OF CBD AND WNT/β-CATENIN PATHWAY IN SARS-COV-2

In parallel, the WNT/β-catenin pathway is upregulated in severe sepsis-induced acute lung injury and sepsis mouse models (56, 57). The WNT/β-catenin pathway is dysregulated in sepsis or ARDS and therefore plays a major role in fibrosis and inflammation (58, 59). In COVID-19 patients, the transforming growth factor (TGFB) stimulates the WNT/β-catenin pathway, leading to an increased risk of pulmonary fibrosis (59) and pulmonary infection (60, 61). The name WNT is derived from Wingless drosophila melanogaster and its mouse homolog Int. The WNT/β-catenin pathway is involved in several mechanisms, controlling signaling, including embryogenesis, cell proliferation, migration and polarity, apoptosis, and

TWO PATHWAYS COULD EXPLAIN THE POSSIBLE ACTIONS OF CBD IN SARS-COV-2 INFECTION BY DOWNREGULATING THE CYTOKINE STORM

CBD and PPARγ in SARS-CoV-2

A recent finding has shown that CBD can reduce both the expression of ACE-2 and RhoA-GTPase/Caspase-1/NLRP3 signaling through its interaction with PPARγ in Caco-2 cells, as intestinal epithelium cells in vitro. This interaction leads to

Table 1 | Actions of CBD in different preclinical studies in COVID-19.

| Property                  | Model                                      | Findings                                      | References |
|---------------------------|--------------------------------------------|-----------------------------------------------|------------|
| Anti-inflammatory         | Human 3D skin artificial tissue model      | Downregulation of COX2, TNF-α, IL-6, CCL2    | (28)       |
| Anti-inflammatory         | Lung epithelial cell                      | Decrease cytokine secretion (IL-6, IL-8)      | (29)       |
| Anti-inflammatory         | Intranasal Poly I:C-induced ARDS.         | Decrease cytokine secretion                    | (30)       |
| Anti-inflammatory         | 3D tissue models                          | Modulation of TMPRSS2 and ACE2 levels         | (31)       |
| Anti-inflammatory         | Intranasal Poly I:C-induced ARDS.         | Decrease cytokine secretion                    | (32)       |
| Anti-inflammatory         | Caco-2-cells                              | Decrease activity of SARS-CoV-2 spike protein by a PPARγ-dependent action | (33) |
| SARS-CoV-2 anti-replication | AS49 human lung cells                     | Blockage in viral replication                 | (13)       |
| SARS-CoV-2 anti-replication | Lung cells                                | Antagonism of SARS-CoV-2Mpro and agonism of CB2 receptor | (27) |
| Antiviral effect          | Human lung fibroblasts                    | Preventive therapy                            | (34)       |

SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; IL, interleukin; ACE2, angiotensin-converting enzyme 2; ARDS, acute respiratory disease syndrome; PPARγ, peroxisome proliferator-activated receptor gamma.
organogenesis (62). The WNT/β-catenin pathway can be damaged in many pathological diseases, including inflammation, metabolic, neurological, and psychiatric disorders, fibrosis, and cancer (63, 64). Numerous findings have observed that the WNT/β-catenin pathway and PPARγ act in an opposing manner in disorders, such as chronic inflammation and fibrosis mechanisms (65, 66) and also SARS-CoV-2 infection (18). Numerous reports have shown that PPARγ agonists could be candidates for modulating the cytokine storm in the COVID-19 disease (67–69), whereas the WNT/β-catenin pathway can stimulate the cytokine storm release (for review, see (18)).

Moreover, the dysregulation in ACE2 expression in lung tissue may exacerbate outcomes in COVID-19 patients (70). In COVID-19 patients, ACE2 expression and the WNT/β-catenin pathway appeared to be interrelated (18). Rats with renal ischemia/reperfusion-induced injury tissue treated by pioglitazone, a PPARγ agonist, have shown a modulation of both ACE2 expression and WNT/β-catenin pathway decrease (71). Even though very few studies have so far shown the potential action of PPARγ agonists in the treatment of COVID-19, rosiglitazone can complement to treat patients already affected by SARS-CoV-2 infection. The possible effects of CBD through its relationship with both the WNT/β-catenin pathway and PPARγ expression should be investigated to better understand its downregulating role on the cytokine storm in SARS-CoV-2 infection. Moreover, more evidence is needed for the routine use of CBD in the treatment of COVID-19 and future clinical trials should be implemented to show its effectiveness.

**CONCLUSION**

The use of CBD to decrease the severity of the SARS-CoV-2 infection based on reported preclinical studies, in addition to the use of vaccines, should be investigated to reinforce the protection against COVID-19. We can hypothesize that CBD may have a possible action to counteract the inflammatory response in SARS-CoV-2 infection. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible effects of CBD through its relationship with both the WNT/β-catenin pathway and PPARγ expression should be investigated to better understand its downregulating role on the cytokine storm in SARS-CoV-2 infection. Moreover, more evidence is needed for the routine use of CBD in the treatment of COVID-19 and future clinical trials should be implemented to show its effectiveness.

**REFERENCES**

1. El-Sayed A, Kamel M. Coronavirus in Humans and Animals: The Role of Bats in Viral Evolution. *Environ Sci Pollut Res Int* (2021) 28:19589–600. doi: 10.1007/s11356-021-12553-1
2. Morrison AR, Johnson JM, Griebe KM, Jones MC, Stine JJ, Hencken LN, et al. Clinical Characteristics and Predictors of Survival in Adults With Coronavirus Disease 2019 Receiving Tocilizumab. *J Autoimmun* (2020) 114:102512. doi: 10.1016/j.jauto.2020.102512
3. Roumier M, Paule R, Valler A, Rohmer J, Ballester M, Brun A-L, et al. Tocilizumab for Severe Worsening COVID-19 Pneumonia: A Propensity Score Analysis. *J Clin Immunol* (2020) 41:303–14. doi: 10.1007/s10875-020-09911-6
4. Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, et al. The Potential of Cannabidiol in the COVID-19 Pandemic. *Br J Pharmacol* (2020) 177:4967–70. doi: 10.1111/bph.15157
5. Onay A, Ertas A, Süzerer V, Yener I, Yılmaz MA, Ayaz-Tılkat E, et al. Cannabidiols for SARS-CoV-2 and is There Evidence of Their Therapeutic Efficacy? *Turk J Biol Turk Biol Derg* (2021) 45:570–87. doi: 10.3906/biy-2105-73
6. Shahbazi F, Grandi V, Banerjee A, Trant JF. Cannabinoids and Cannabinoid Receptors: The Story So Far. *sciencemag.org* (2020) 23:101301. doi: 10.1016/j.jsic.2020.101301
7. Nelson KM, Dahlin BL, Bisson I, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. *J Med Chem* (2017) 60:1620–37. doi: 10.1021/acs.jmedchem.6b00975
8. Sekar K, Pack A. Epidiolex as Adjunct Treatment for Treatment of Refractory Epilepsy: A Comprehensive Review With a Focus on Adverse Effects. *F1000Research* (2019) 8:F1000 Faculty Rev–234. doi: 10.12688/f1000research.16515.1
9. Lowe HIC, Toyang NJ, McLaughlin W. Potential of Cannabidiol for the Treatment of Viral Hepatitis. *Pharmacog Res* (2017) 9:116–8. doi: 10.4103/0974-8490.199780
10. Mabou Tagne A, Pacchetti B, Sodergren M, Cosentino M, Marino F. Cannabidiol for Viral Diseases: Hype or Hope? *Cannabis Cannabinoid Res* (2020) 5:121–31. doi: 10.1089/can.2019.0060
11. Naqui AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Hassan MdI. Insights Into SARS-CoV-2 Genome, Structure, Evolution, Pathogenesis and Therapies: Structural Genomics Approach. *Biochim Biophys Acta Mol Basis Dis* (2020) 1866:165878. doi: 10.1016/j.bbadis.2020.165878
12. Parks JM, Smith JC. How to Discover Antiviral Drugs Quickly. *N Engl J Med* (2020) 382:2261–4. doi: 10.1056/NEJMcb2007042
13. Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D, et al. Cannabidiol Inhibits SARS-CoV-2 Replication Through Induction of the Host ER Stress and Innate Immune Responses. *Sci Adv* (2022) 8.eaah6110. doi: 10.1126/sciadv.aah6110
14. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1–9. *Circ Res* (2000) 87:E1–9. doi: 10.1161/01.res.87.5.e1
15. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie A, Turner AJ. A Human Homolog of Angiotensin-Converting Enzyme. Cloning and Functional Expression as a Captopril-Inensitive Carboxypeptidase. *J Biol Chem* (2000) 275:33238–43. doi: 10.1074/jbc.M002615200
16. Wijnant SRA, Jacobs M, Van Eckhoutte HP, Lapauw B, Joos GF, Bracke KR, et al. Expression of ACE2, the SARS-CoV-2 Receptor, in Lung Tissue of Patients With Type 2 Diabetes. *Diabetes* (2020) 69:2691–9. doi: 10.2337/db20-0669
17. Lecarpentier Y, Valle J-N. Interplay of Opposing Effects of the WNT/β-Catenin Pathway and Pparg and Implications for SARS-CoV2 Treatment. *Front Immunol* (2021) 12:666693. doi: 10.3389/fimmu.2021.666693

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

Conceptualization, AV. Writing—original draft preparation, AV. The author has read and agreed to the published version of the manuscript.
Raj V, Park JG, Cho K-H, Choi P, Kim T, Ham J, et al. Assessment of Antiviral... 2020:181:270–280.e8. doi: 10.1002/j.2020.02.052

20. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor. Nature (2020) 581:215–20. doi: 10.1038/s41586-020-2180-5

21. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human Ace2. Cell (2020) 181:894–904.e9. doi: 10.1016/j.cell.2020.03.045

22. Badawi S, Ali BR. ACE2 Nascence, Trafficking, and SARS-CoV-2 Pathogenesis: The Saga Continues. Hum Genomics (2021) 15:18. doi: 10.1186/s40426-021-00364-9

23. Smith JC, Saussville EL, Girsch V, Yuan ML, Vasudevan A, John KM, et al. Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract. Dev Cell (2020) 53:514–529.e3. doi: 10.1016/j.devcel.2020.05.012

24. Carnevale S, Beretta P, Morbini P. Direct Endothelial Damage and Vasculitis Due to SARS-CoV-2 in Small Bowel Submucosa of COVID-19 Patient With Diarrhea. J Med Virol (2021) 93:61–3. doi: 10.1002/jmv.26119

25. Romano M, Ruggiero A, Squeglia F, Maga G, Berisso R. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells (2020) 9:E1267. doi: 10.3390/cells9051267

26. Zhang L, Liu D, Sun X, Curth U, Drost C, Sauhertering I, et al. Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved α-Ketoamide Inhibitors. Science (2020) 368:409–12. doi: 10.1126/science.abb3405

27. Raj V, Park JG, Cho K-H, Choi P, Kim T, Ham J, et al. Assessment of Antiviral Potencies of Cannabinoids Against SARS-CoV-2 Using Computational and In Vitro Approaches. Int J Biol Macromol (2021) 168:474–85. doi: 10.1016/j.jbiomac.2020.12.020

28. Kovalchuk A, Wang B, Li D, Rodriguez-Juarez R, Ilnytskyy S, Kovalchuk I, et al. Fighting the Storm: Could Novel Anti-Tnf and Anti-IL-6 C. Sativa Cultivars Tame Cytokine Storm in COVID-19? J Immunol Res (2020) 2019:843:251–9. doi: 10.1155/2018.11.029

29. Bifulco M, Fiore D, Pescopo C, Gazzero F, Proto MC. Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019. Front Pharmacol (2021) 12:631646. doi: 10.3389/fphar.2021.631646

30. Nichols JM, Kaplan BLF. Immune Responses Regulated by Cannabidiol. Cannabis Cannabinoid Res (2020) 5:12–31. doi: 10.1089/can.2018.0077

31. Vuolo F, Abreu SC, Michels M, Xisto DG, Blanco NG, Hallak JE, et al. Cannabidiol Reduces Airway Inflammation and Fibrosis in Experimental Allergic Asthma. Eur J Pharmacol (2019) 843:251–9. doi: 10.1016/j.ejphar.2018.11.029

32. Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, et al. Interferon-γb Treatment for COVID-19. Front Immunol (2020) 11:1061. doi: 10.3389/fimmu.2020.01061

33. Costiniuk CT, Jenabian M-A. Acute Inflammation and Pathogenesis of SARS-CoV-2 Infection: Cannabidiol as a Potential Anti-Inflammatory Treatment? Cytokine Growth Factor Rev (2020) 53:63–5. doi: 10.1016/j.cytogfr.2020.05.008

34. Chatow L, Nudel A, Nesher I, Hayo Hemo D, Rozenberg P, Voropaev H, et al. Cannabidiol and SARS-CoV-2: Spike Receptor-Binding Domain Bound to the ACE2 Receptor. Nature (2020) 581:215–20. doi: 10.1038/s41586-020-2180-5

35. Muthumalage T, Rahman I. Cannabidiol Differentially Regulates Basal and LPS-Induced Inflammatory Responses in Macrophages, Lung Epithelial Cells, and Fibroblasts. Toxicol Appl Pharmacol (2019) 382:114713. doi: 10.1016/j.taap.2019.114713

36. Barichello T, Ceretta RA, Generoso JS, Moreira AP, Simões LR, Comim CM, et al. Cannabidiol Reduces Host Immune Response and Prevents Cognitive Impairments in Wistar Rats Submitted to Pneumococcal Meningitis. Eur J Pharmacol (2020) 872:158–64. doi: 10.1016/j.ejphar.2012.09.053

37. Lee C-H, Olson P, Evans RM. Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors. Front Pharmacol (2021) 12:631646. doi: 10.3389/fphar.2021.631646

38. Patki M, Patel K. Cannabidiol Inhibits Airway Inflammation and Fibrosis in Experimental Allergic Asthma. Br J Clin Pharmacol (2019) 85:1888–900. doi: 10.1111/bcp.14038

39. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK, et al. Wnt5A/CaMKII Supresses Long-Term Lung Fibrotic Sequelae Following Acute Respiratory Distress Syndrome. J Cell Mol Med (2020) 24:12245–44. doi: 10.1186/s12075-022-0649-2

40. Carnevale S, Beretta P, Morbini P. Direct Endothelial Damage and Vasculitis Due to SARS-CoV-2 in Small Bowel Submucosa of COVID-19 Patient With Diarrhea. J Med Virol (2021) 93:61–3. doi: 10.1002/jmv.26119

41. Bifulco M, Fiore D, Pescopo C, Gazzero F, Proto MC. Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019. Front Pharmacol (2021) 12:631646. doi: 10.3389/fphar.2021.631646

42. Carnevale S, Beretta P, Morbini P. Direct Endothelial Damage and Vasculitis Due to SARS-CoV-2 in Small Bowel Submucosa of COVID-19 Patient With Diarrhea. J Med Virol (2021) 93:61–3. doi: 10.1002/jmv.26119

43. Corpetti C, Del Re A, Seguella L, Palenga I, Rungroj D, Conosco R, et al. Cannabidiol Inhibits SARS-CoV-2 Spike (S) Protein-Induced Cytotoxicity and Inflammation Through a Ppar-Dependent Tlr4/Nlrp3/Caspase-1 Signaling Suppression in Caco-2 Cell Line. Phytother Res PTR (2021) 35:6893–903. doi: 10.1002/ptr.7302

44. Chatow L, Nudel A, Nesher I, Hayo Hemo D, Rosenberg P, Voropaev H, et al. In Vitro Evaluation of the Activity of Terpenes and Cannabidiol Against SARS-CoV-2 Infection: Cannabidiol as a Potential Anti-Inflammatory Treatment? Cytokine Growth Factor Rev (2020) 53:63–5. doi: 10.1016/j.cytogfr.2020.05.008
Target for the Antiinflammatory Action of Activated Protein C and Interleukin-10. *Arterioscler Thromb Vasc Biol* (2008) 28:504–10. doi: 10.1161/ATVBAHA.107.157438

57. Gatica-Andrades M, Vagenas D, Kling J, Nguyen TTK, Benham H, Thomas R, et al. WNT Ligands Contribute to the Immune Response During Septic Shock and Amplify Endotoxemia-Driven Inflammation in Mice. *Blood Adv* (2017) 1:1274–86. doi: 10.1182/bloodadvances.2017006163

58. Villar J, Cabrera-Benitez NE, Ramos-Nuez A, Flores C, Garcia-Hernandez S, Valladares F, et al. Early Activation of Pro-Fibrotic WNT5A in Sepsis-Induced Acute Lung Injury. *Crit Care Lond Engl* (2014) 18:568. doi: 10.1186/s13054-014-0568-z

59. Newman DR, Sills WS, Hanrahan K, Ziegler A, Tidd KM, Cook E, et al. Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-β and WNT7B in Human Lung Fibroblasts. *J Histochem Cytochem Off J Histochem Soc* (2016) 64:99–111. doi: 10.1369/0022155415617988

60. Choi EY, Park HH, Kim H, Kim HN, Kim I, Jeon S, et al. Wnt5a and Wnt11 as Acute Respiratory Distress Syndrome Biomarkers for Severe Acute Respiratory Syndrome Coronavirus 2 Patients. *Eur Respir J* (2020) 56(5). doi: 10.1183/13993003.01531-2020

61. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. *Cell* (2020) 182:59–72.e15. doi: 10.1016/j.cell.2020.05.032

62. Loh KM, van Amerongen R, Nusse R. Generating Cellular Diversity and Potential Consequences for Development and Disease. *Cell* (2016) 168:e1–2. doi: 10.1016/j.devcel.2016.08.011

63. Clevers H, Nusse R. Wnt/β-Catenin Signaling and Disease. *Cell* (2012) 149:1192–205. doi: 10.1016/j.cell.2012.05.012

64. Ma B, Hottiger MO. Crosstalk Between Wnt/β-Catenin and NF-kB Signaling Pathway During Inflammation. *Front Immunol* (2016) 7:378. doi: 10.3389/fimmu.2016.00378

65. Vallée A, Lecarpentier Y, Vallée J-N. Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism During the Fibrosis Process. *Int J Mol Sci* (2017) 18(12):2537. doi: 10.3390/ijms18122537

66. Vallée A, Lecarpentier Y. Crosstalk Between Peroxisome Proliferator-ACTivated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis. *Front Immunol* (2018) 9:745. doi: 10.3389/fimmu.2018.00745

67. Ciavarella C, Motta I, Valent e S, Pasquinelli G. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease. *Molecules* (2020) 25(9):2076. doi: 10.3390/molecules25092076

68. Costa FF, Rosário WR, Ribeiro Farias AC, de Souza RG, Duarte Gondim RS, Barroso WA. Metabolic Syndrome and COVID-19: An Update on the Associated Comorbidities and Proposed Therapies. *Diabetes Metab Syndr* (2020) 14:809–14. doi: 10.1016/j.dsx.2020.06.016

69. Francisquetti-Ferron FV, Garcia JL, Ferron AJT, Nakandakare-Maia ET, Gregolin CS, Silva JP, et al. Gamma-Oryzanol as a Potential Modulator of Oxidative Stress and Inflammation via PPAR-Y in Adipose Tissue: A Hypothetical Therapeutic for Cytokine Storm in COVID-19? *Mol Cell Endocrinol* (2021) 520:111095. doi: 10.1016/j.mce.2020.111095

70. Kuba K, Yamaguchi T, Penninger JM. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19. *Front Immunol* (2021) 12:732690. doi: 10.3389/fimmu.2021.732690

71. Ali RM, Al-Shorbagy MY, Helmy MW, El-Abhar HS. Role of Wnt4/β-Catenin, Ang I/II/Tgfβ, ACE2, NF-kB, and IL-18 in Attenuating Renal Ischemia/Reperfusion-Induced Injury in Rats Treated With Vit D and Pioglitazone. *Eur J Pharmacol* (2018) 831:68–76. doi: 10.1016/j.ejphar.2018.04.032

72. Filardi T, Morano S. COVID-19: Is There a Link Between the Course of Infection and Pharmacological Agents in Diabetes? *J Endocrinol Invest* (2020) 43:1053–60. doi: 10.1007/s40618-020-01318-1

73. Ceriello A, Studi E, Catrinoiu D, Itzhak B, Lalic NM, Rahelic D, et al. Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Issues of Infection and Pharmacological Agents in Diabetes? *Diabetes Care* (2020) 43:1427–32. doi: 10.2337/dc20-0941

Conflict of Interest: The author declares that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Vallée. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.